Atypical hemolytic uremic syndrome Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

10 events

Apr 2026Ravulizumab Outcomes in Polish Patients With aHUS

AstraZeneca

TrialNOT YET RECRUITING

Dec 2025Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Alexion Pharmaceuticals, Inc. — PHASE4

TrialRECRUITING

Oct 2025The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

AstraZeneca — NA

TrialRECRUITING

Jul 2025Study of NM8074 in Patients with AHUS with Evidence of Ongoing Thrombotic Microangiopathy

NovelMed Therapeutics — PHASE2

TrialNOT YET RECRUITING

Feb 2024Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Novartis Pharmaceuticals — PHASE3

TrialRECRUITING

Jan 2024A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients

AstraZeneca

TrialACTIVE NOT RECRUITING

Nov 2023Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

Assistance Publique - Hôpitaux de Paris — PHASE3

TrialRECRUITING

Jul 2023New Analytic Tools for aHUS and C3G Diagnosis

Mario Negri Institute for Pharmacological Research — NA

TrialACTIVE NOT RECRUITING

May 2023Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

Mario Negri Institute for Pharmacological Research — NA

TrialRECRUITING

Nov 2021A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Hoffmann-La Roche — PHASE3

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

3 programs

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs3

SOLIRIS

Alexion Pharmaceuticals Inc.

OpenContact for detailsApply ↗

BKEMV

Amgen Inc

OpenContact for detailsApply ↗

Ultomiris

Alexion Pharmaceuticals Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

4 FDA-approved

SOLIRIS

(ECULIZUMAB)Orphan drug

Alexion Pharmaceuticals Inc.

Approved Sep 2011FDA label ↗

BKEMV

(ECULIZUMAB-AEEB)Orphan drugstandard

Amgen Inc

FDA label ↗

EPYSQLI

(ECULIZUMAB-AAGH)Orphan drugstandard

Teva Pharmaceuticals USA, Inc.

FDA label ↗

Ultomiris

(RAVULIZUMAB)Orphan drugstandard

Alexion Pharmaceuticals Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

10 active trials

3Phase 3

1Phase 4

3N/A

3Unknown

10Total recruiting

Search clinical trials for Atypical hemolytic uremic syndrome →

Recent News & Research

No recent news articles indexed yet for Atypical hemolytic uremic syndrome.
Search PubMed for Atypical hemolytic uremic syndrome →

Browse all Atypical hemolytic uremic syndrome news →

Specialist Network

Top 6 by expertise

Marina Noris, PhD

Istituto Di Ricerche Farmacologiche Mario Negri

Score 342 trials

Sonata Jodele, MD, M.D

Children's Hospital Medical Center, Cincinnati

📍 CINCINNATI, OH

Score 211 trial

Giuseppe Remuzzi, MD

Istituto Di Ricerche Farmacologiche Mario Negri

Score 77 trials

Nuria Saval

Alexion Pharmaceuticals, Inc.

Score 51 trial

Nader Najafian, MD, MD

Alnylam Pharmaceuticals

📍 BOSTON, MA

Score 53 trials

Raymond Vanholder, MD, PhD

University Hospital Ghent, Belgium

Score 33 trials

View all Atypical hemolytic uremic syndrome specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰